Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator.
about
Opioid-induced constipation: advances and clinical guidanceCurrent developments in pharmacological therapeutics for chronic constipationTreatment for constipation: new and old pharmacological strategiesClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic targetChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsLubiprostone stimulates duodenal bicarbonate secretion in ratsProstaglandin E2-induced colonic secretion in patients with and without colorectal neoplasiaLubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.New horizons in the treatment of cystic fibrosis.Research and progress on ClC‑2 (Review).Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.Recent advances in pharmacological treatment of irritable bowel syndrome.Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.Effects of lubiprostone on pacemaker activity of interstitial cells of cajal from the mouse colon.Activated fluid transport regulates bacterial-epithelial interactions and significantly shifts the murine colonic microbiome.Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndromeLubiprostone stimulates small intestinal mucin release.Inhibition of Heat-Stable Toxin-Induced Intestinal Salt and Water Secretion by a Novel Class of Guanylyl Cyclase C Inhibitors.Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies.Lubiprostone targets prostanoid EP₄ receptors in ovine airways.Lubiprostone in constipation: clinical evidence and place in therapy.Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosaSevere defects in absorptive ion transport in distal colons of mice that lack ClC-2 channels.Advancing treatment options for chronic idiopathic constipation.New and Emerging Treatment Options for Irritable Bowel Syndrome.Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestineDual activation of CFTR and CLCN2 by lubiprostone in murine nasal epitheliaCFTR activator increases intestinal fluid secretion and normalizes stool output in a mouse model of constipationThe cystic fibrosis intestine.Lubiprostone for the treatment of adult women with irritable bowel syndrome with constipation.Evidence for intestinal chloride secretion.Behavioural and new pharmacological treatments for constipation: getting the balance rightRegulation of electroneutral NaCl absorption by the small intestineLubiprostone for the treatment of adults with constipation and irritable bowel syndrome.Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.Toxin mediated diarrhea in the 21 century: the pathophysiology of intestinal ion transport in the course of ETEC, V. cholerae and rotavirus infection.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
P2860
Q26765571-EA877E14-5AAA-4DF0-B0F4-B91BF29DCEB1Q27025474-94EAD401-36EB-4505-9CB7-8C5CB181BAE5Q27027346-F8E66E94-C5B8-4447-87D2-5C66E352E6C2Q28066092-5A8E99D0-4D03-41C2-AAA3-4B81C1A20627Q28079705-78F9C264-500B-4DC8-9AE2-2B17B005E432Q28572915-0052347B-230F-435B-BEEA-F1B643E989A8Q33526510-F87CEF17-2080-44D2-9E91-001F79EE92B3Q33693282-3FFBA27E-229D-4856-80CC-E41A14EBD6E5Q33752154-72650F24-D745-45FD-AE61-382BE10DCCBFQ33756002-84E9B9D6-1732-4CF9-8CD5-0A1186D7789DQ33828111-933A6F88-EE02-4B6C-9F5C-AB73411F02B4Q33958710-67C1553C-D56E-40F8-9E13-7BA248B56244Q33958853-90FB1084-2E58-4AB3-B6C2-2682F5E5E0D4Q34028142-80167C19-7D48-4E01-868C-69C8C7C67E4AQ34097910-302ECE65-A2BB-48B9-AA5A-95C62C7474D7Q34276638-9EBE7BBE-3971-4E1C-A67B-886F17B43F07Q34345704-CC52BCF3-DC6B-4B4C-8411-11D25E647E7EQ34468167-E56F49CA-A1C5-43C9-8D8F-F5560F2FC9C0Q34477345-D9963A6B-78BF-4A94-B733-24EF4A6F0C34Q34522966-15C3401A-FCA7-46D6-BEC8-CE2EEDDBC52FQ34540238-5C2C4C3F-8F03-4D8E-AA7F-BC1E3E596153Q35091370-AA4EA26C-5FC2-4AE3-870C-3721ADDA6155Q35482151-05332CA5-48E9-47A0-B007-8E7AB4C2E9C2Q35664952-2071ECC9-7213-4499-9FB7-D9C03CAE0072Q35705381-146C0ACA-8FC5-4A64-A149-B7000CCEC877Q35858864-E293DD3B-8DC9-4F1C-838A-717F43ACA23EQ36180769-6B3369F0-D4CD-4050-923D-BA90547F0E5AQ36371798-4F3D9ACD-93E0-490D-B1B1-1244F39EF803Q36590527-F8F97C94-9E5F-4346-97A8-9F692BDA8ADBQ36699974-BD87D8F8-DFFB-4B08-B3D8-A4F6DADE869BQ36833766-7D0FF4D3-C7B7-4D24-B674-6002E5180EBAQ37122355-40D4C53F-4C82-4F08-B777-598F9314CD66Q37704523-6AC1D43C-B524-4CE8-990A-6D70B0647911Q37710221-883DC9C5-CB5C-4BCD-AE0D-F5BA6DD64FA9Q37783838-6985BE40-D117-47F4-BD0D-A8BBDF5D83C5Q37807415-A7B84673-3590-4C95-84EA-D1FDA253FBCCQ37869371-8F0A2A56-88E7-4103-800A-1329C6748D60Q37886156-EF7091C0-79C7-41C5-8332-2620CFF42D3BQ37954317-814E5226-74F2-4FB4-B4F1-F302277BBFE3Q37954521-21FAE7C3-2221-4B45-B59A-E3A45A20ED43
P2860
Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Activation of intestinal Cl- s ...... embrane conductance regulator.
@en
Activation of intestinal Cl- s ...... embrane conductance regulator.
@nl
type
label
Activation of intestinal Cl- s ...... embrane conductance regulator.
@en
Activation of intestinal Cl- s ...... embrane conductance regulator.
@nl
prefLabel
Activation of intestinal Cl- s ...... embrane conductance regulator.
@en
Activation of intestinal Cl- s ...... embrane conductance regulator.
@nl
P2093
P921
P1433
P1476
Activation of intestinal Cl- s ...... embrane conductance regulator.
@en
P2093
Alice G M Bot
Hugo R De Jonge
Johanna C Escher
Marcel J C Bijvelds
P304
P356
10.1053/J.GASTRO.2009.05.037
P407
P577
2009-05-18T00:00:00Z